These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31281650)

  • 1. Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer.
    Tajima H; Ohta T; Okazaki M; Yamaguchi T; Ohbatake Y; Okamoto K; Nakanuma S; Kinoshita J; Makino I; Nakamura K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Nakamura H
    Mol Clin Oncol; 2019 Aug; 11(2):157-166. PubMed ID: 31281650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.
    Tajima H; Ohta T; Kitagawa H; Okamoto K; Sakai S; Makino I; Kinoshita J; Furukawa H; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Fushida S; Tani T; Fujimura T; Ikeda H; Kitamura S
    Exp Ther Med; 2012 May; 3(5):787-792. PubMed ID: 22969969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
    Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
    Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus
    Tajima H; Makino I; Gabata R; Okazaki M; Ohbatake Y; Shimbashi H; Nakanuma S; Saitoh H; Shimada M; Yamaguchi T; Okamoto K; Moriyama H; Kinoshita J; Nakamura K; Miyashita T; Ninomiya I; Fushida S; Ikeda H; Ohta T
    Mol Clin Oncol; 2021 Feb; 14(2):26. PubMed ID: 33414907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
    Liu H; D'Alesio M; AlMasri S; Hammad A; Desilva A; Lebowitz S; Rieser C; Ashwat E; Hampton E; Khachfe H; Laffey M; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
    HPB (Oxford); 2023 May; 25(5):521-532. PubMed ID: 36804826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study.
    Xu D; Wang J; Liu T; Huang Z; Luo J; Chen Y; Lu Y
    Gland Surg; 2021 Feb; 10(2):770-779. PubMed ID: 33708559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report.
    Murokawa T; Okabayashi T; Sui K; Tabuchi M; Iwata J
    Surg Case Rep; 2022 Feb; 8(1):29. PubMed ID: 35171354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
    Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
    Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
    Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
    Front Oncol; 2020; 10():1112. PubMed ID: 32850319
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.
    Scheufele F; Hartmann D; Friess H
    Transl Gastroenterol Hepatol; 2019; 4():32. PubMed ID: 31231699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.
    Ono Y; Inoue Y; Ito H; Sasaki T; Takeda T; Ozaka M; Sasahira N; Hiratsuka M; Matsueda K; Oba A; Sato T; Saiura A; Takahashi Y
    HPB (Oxford); 2023 Jan; 25(1):100-108. PubMed ID: 36280425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study.
    Murakami M; Fujimori N; Ohno A; Matsumoto K; Teramatsu K; Takamatsu Y; Takeno A; Oono T; Abe T; Ideno N; Ikenaga N; Nakata K; Nakamura M; Ishigami K; Ogawa Y
    Discov Oncol; 2022 Jan; 13(1):2. PubMed ID: 35201490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis.
    Naito Y; Ishikawa H; Sadashima E; Okabe Y; Takahashi K; Kawahara R; Hisaka T; Fukahori M; Ushijima T; Ishida Y; Tanigawa M; Mihara Y; Nakayama M; Kondo R; Kusano H; Takase Y; Abe H; Ogo E; Okuda K; Shimamatsu K; Yano H; Akiba J
    Mol Clin Oncol; 2019 Sep; 11(3):225-233. PubMed ID: 31423309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Carcinoma Followed by Pancreatectomy with Portal Vein Resection and Reconstruction with Venous Allograft.
    Huang JC; Pan B; Wang HX; Chen Q; He Q; Lyu SC
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kelley JK; Kolbeinsson H; Chandana S; Eastburg B; Frisch A; Parker J; Wright GP; Assifi MM; Chung M
    Am Surg; 2024 Apr; ():31348241250043. PubMed ID: 38676648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
    Ye M; Zhang Q; Chen Y; Fu Q; Li X; Bai X; Liang T
    HPB (Oxford); 2020 Jun; 22(6):821-832. PubMed ID: 32001139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.